In a research center in Magdeburg, Germany, older adults are quietly taking memory tests on their smartphones at home—a shift that could reshape how doctors spot the earliest signs of dementia. A new study from the German Center for Neurodegenerative Diseases (DZNE), conducted in collaboration with university hospitals in Germany, the University of Wisconsin–Madison, and the startup neotiv, shows that app-based cognitive tests can detect the subtle mental decline associated with mild cognitive impairment faster and more frequently than traditional in-person testing. This matters because people with mild cognitive impairment, or MCI, carry significantly higher risk of developing dementia, and catching subtle changes early could accelerate the development of new Alzheimer's drugs and transform how doctors monitor cognitive health.
The conventional approach to testing cognitive decline has remained largely unchanged for decades. Patients visit clinics, sit down with a neuropsychologist, and complete standardized tasks on paper or by speaking aloud—a process that is time-consuming, logistically demanding, and typically happens only once or twice a year. By contrast, the research team used the neotivTrials app, a smartphone application based on DZNE research, to measure what researchers call "digital biomarkers"—measurable signals of cognitive function captured through everyday technology. "By contrast, the current study involved self-administered at-home memory tests using the neotivTrials app, which allows us to collect what are known as digital biomarkers," explains Dr. David Berron, who leads a research group at DZNE's Magdeburg site and is a co-founder of neotiv.
The study tracked 202 older adults aged 52 to 85 from Germany and the United States over roughly seven to twelve months. Fifty of these participants had been diagnosed with mild cognitive impairment. Rather than visiting a clinic, these individuals tested themselves on their smartphones approximately every two weeks, using an app that required only a smartphone or tablet and could be completed at their own pace, in their own homes. What emerged from the data was striking: the frequent, remote measurements could detect cognitive decline in MCI patients within months—a timeframe that conventional testing, with its once or twice yearly assessments, would likely miss entirely.
The researchers validated their findings against long-term clinical data spanning an average of eight years for each participant, gathered using established clinical procedures. The cognitive trajectories predicted by just a few months of app-based testing aligned closely with the long-term patterns documented over years of traditional testing—powerful evidence that the smartphone approach genuinely measures what it claims to measure. "From a medical perspective, what matters is not only whether MCI is present, but also whether the symptoms remain stable or worsen," Berron notes. For drug developers testing new dementia treatments, this acceleration could be transformative. Clinical trials typically must run for months or years to detect meaningful cognitive changes; high-frequency digital testing compresses that timeline.
Beyond clinical research, the implications extend into everyday medical practice. Dr. Sarah Polk, the study's first author, highlights the practical advantage: "Testing can be done at home, at your own pace. All you need is a smartphone or tablet—there's no need to visit a study center or make an appointment." This accessibility could democratize cognitive monitoring, bringing regular neuropsychological assessment to people in rural areas or those with mobility constraints. While this particular study used one specific app, the findings suggest a broader future in which remote digital tools become standard tools for detecting and tracking cognitive change—making early intervention possible for millions.